IGMS IGM Biosciences, Inc.

IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.

$18.61  -0.33 (-1.74%)
As of 06/28/2022 15:23:35 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/28/2019
Outstanding shares:  27,399,763
Average volume:  289,414
Market cap:   $527,445,438
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BKS3SM8
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.06
PS ratio:   0.00
Return on equity:   -90.66%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy